State Street Corp trimmed its position in Shire PLC (NASDAQ:SHPG) by 6.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 418,433 shares of the biopharmaceutical company’s stock after selling 28,062 shares during the period. State Street Corp’s holdings in Shire PLC were worth $69,154,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of SHPG. American International Group Inc. grew its position in Shire PLC by 1.2% in the 1st quarter. American International Group Inc. now owns 4,607 shares of the biopharmaceutical company’s stock valued at $803,000 after buying an additional 54 shares during the last quarter. Vanguard Group Inc. grew its position in Shire PLC by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after buying an additional 13,665 shares during the last quarter. Geode Capital Management LLC grew its position in Shire PLC by 14.0% in the 1st quarter. Geode Capital Management LLC now owns 51,062 shares of the biopharmaceutical company’s stock valued at $8,896,000 after buying an additional 6,258 shares during the last quarter. BlackRock Inc. grew its position in Shire PLC by 4,217.7% in the 1st quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after buying an additional 1,400,275 shares during the last quarter. Finally, Independent Portfolio Consultants Inc. grew its position in Shire PLC by 27.8% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after buying an additional 354 shares during the last quarter. Hedge funds and other institutional investors own 19.27% of the company’s stock.
Shire PLC (SHPG) opened at 142.17 on Monday. The stock’s 50 day moving average price is $152.36 and its 200 day moving average price is $163.12. Shire PLC has a 1-year low of $137.80 and a 1-year high of $192.64. The firm has a market cap of $42.35 billion, a P/E ratio of 63.61 and a beta of 1.63.
Shire PLC (NASDAQ:SHPG) last announced its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.64 by $0.17. Shire PLC had a return on equity of 14.73% and a net margin of 10.95%. The business had revenue of $3.70 billion during the quarter. During the same period in the prior year, the business earned $3.17 EPS. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. Equities research analysts predict that Shire PLC will post $14.92 EPS for the current year.
The company also recently announced a semiannual dividend, which was paid on Friday, October 20th. Investors of record on Friday, September 8th were paid a dividend of $0.1527 per share. The ex-dividend date was Thursday, September 7th. This represents a yield of 0.21%. Shire PLC’s dividend payout ratio is currently 17.23%.
A number of equities analysts recently weighed in on the stock. Cowen and Company set a $225.00 price objective on shares of Shire PLC and gave the company a “buy” rating in a research report on Sunday. Cantor Fitzgerald reiterated a “buy” rating and issued a $222.00 price objective on shares of Shire PLC in a research report on Friday. Zacks Investment Research upgraded shares of Shire PLC from a “sell” rating to a “hold” rating in a research report on Friday. Piper Jaffray Companies reiterated a “hold” rating and issued a $160.00 price objective on shares of Shire PLC in a research report on Friday. Finally, ValuEngine upgraded shares of Shire PLC from a “hold” rating to a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $211.00.
TRADEMARK VIOLATION NOTICE: This report was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.com-unik.info/2017/10/30/state-street-corp-has-69-15-million-position-in-shire-plc-shpg.html.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
What are top analysts saying about Shire PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire PLC and related companies.